Whittier Trust Co. Has $5.13 Million Holdings in West Pharmaceutical Services, Inc. $WST

Whittier Trust Co. trimmed its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 56.0% in the 1st quarter, Holdings Channel reports. The fund owned 19,990 shares of the medical instruments supplier’s stock after selling 25,491 shares during the quarter. Whittier Trust Co.’s holdings in West Pharmaceutical Services were worth $5,134,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of WST. Revisor Wealth Management LLC increased its position in West Pharmaceutical Services by 19.2% during the first quarter. Revisor Wealth Management LLC now owns 1,274 shares of the medical instruments supplier’s stock worth $318,000 after acquiring an additional 205 shares during the period. V Square Quantitative Management LLC grew its position in West Pharmaceutical Services by 15.0% in the 1st quarter. V Square Quantitative Management LLC now owns 2,688 shares of the medical instruments supplier’s stock worth $674,000 after purchasing an additional 351 shares during the last quarter. New York State Teachers Retirement System grew its position in West Pharmaceutical Services by 2.9% in the 1st quarter. New York State Teachers Retirement System now owns 60,523 shares of the medical instruments supplier’s stock worth $15,169,000 after purchasing an additional 1,690 shares during the last quarter. Leonteq Securities AG increased its holdings in shares of West Pharmaceutical Services by 6,314.3% during the 1st quarter. Leonteq Securities AG now owns 449 shares of the medical instruments supplier’s stock worth $113,000 after purchasing an additional 442 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of West Pharmaceutical Services by 56.0% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 30,600 shares of the medical instruments supplier’s stock valued at $7,670,000 after buying an additional 10,990 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

Shares of WST traded down $5.36 during trading hours on Tuesday, hitting $352.28. The stock had a trading volume of 103,782 shares, compared to its average volume of 914,981. The stock has a market capitalization of $24.89 billion, a price-to-earnings ratio of 47.10, a P/E/G ratio of 3.06 and a beta of 1.16. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The company’s fifty day moving average is $323.60 and its two-hundred day moving average is $279.56. West Pharmaceutical Services, Inc. has a 52 week low of $206.80 and a 52 week high of $367.66.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period last year, the firm posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

Analyst Ratings Changes

WST has been the topic of several research reports. Wolfe Research assumed coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. Stephens reissued an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. KeyCorp upped their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Evercore reiterated an “outperform” rating and set a $410.00 price target on shares of West Pharmaceutical Services in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $351.91.

Insider Activity at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.